[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:fibrolamellar-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":55,"states":60},"Fibrolamellar Carcinoma",7,6,[8,16,23,29,35,42,48],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06620302","Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-03T02:50:47.306763Z","2026-05-05T02:43:29.510227Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04248569","DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma",[20],"Phase 1","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.359438Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06027086","DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)",[12],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:29.321754Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04380545","Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer",[12],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:28.419779Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT04134559","Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma",[39],"Phase 2","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.799178Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05468359","Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:35:31.864168Z",{"nct_id":49,"title":50,"phases":51,"status":52,"updated_at":53,"content_modified":54},"NCT07430202","A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)",[20],"NOT_YET_RECRUITING","2026-08-26T02:16:27.227548Z","2026-05-05T02:43:26.693770Z",[56],{"biomarker":57,"count":58,"slug":59},"DNAJB1-PRKACA",3,"dnajb1-prkaca",[61,64],{"state":62,"count":58,"slug":63},"Maryland","maryland",{"state":65,"count":58,"slug":66},"Texas","texas"]